Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 clinical trial of VIR-7831 for the prevention of symptomatic COVID-19 infections

Next Previous
X
Search
Trial Profile

A Phase 3 clinical trial of VIR-7831 for the prevention of symptomatic COVID-19 infections

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sotrovimab (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Acronyms COMET-STAR

    • Most Recent Events

    • 09 Aug 2022 According to a Vir Biotechnology media release, due to the evolving COVID-19 landscape and based on discussions with the US Food and Drug Administration (FDA), the Company and GSK do not plan to file a Biologics License Application for sotrovimab at this time and do not intend to pursue the US-based Phase 3 COMET-STAR prophylaxis trial.
    • 24 Feb 2022 According to a Vir Biotechnology media release, Vir in collaboration with GSK is expecting this trial to start in the second quarter of 2022, the analysis of the primary endpoint of COMET-STAR will be event driven, and could be as early as the second half of 2022.
    • 21 May 2021 According to a GlaxoSmithKline media release, this Phase 3 trial is expected to begin in the third quarter of 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top